R
Rakesh K. Jain
Researcher at Harvard University
Publications - 1528
Citations - 198912
Rakesh K. Jain is an academic researcher from Harvard University. The author has contributed to research in topics: Angiogenesis & Cancer. The author has an hindex of 200, co-authored 1467 publications receiving 177727 citations. Previous affiliations of Rakesh K. Jain include Government Medical College, Thiruvananthapuram & University of Oslo.
Papers
More filters
Patent
Methods to potentiate cancer therapies
Brian Seed,Rakesh K. Jain +1 more
TL;DR: In this article, a method for treating cancer in a mammal involving the administration of relaxin and/or γ-IFN peptides and an anti-cancer therapy to the mammal, where the peptide and the therapy are administered at dosages which together are sufficient to destroy, slow, or arrest the cancer.
Journal Article
Effect of Intravenous versus Intraperitoneal Glucose Injection on Systemic Hemodynamics and Blood Flow Rate in Normal and Tumor Tissues in Rats
TL;DR: The effect of i.p. glucose injections on blood flow rate of Walker 256 carcinoma and several normal tissues of unanesthetized, unrestrained female Sprague-Dawley rats was measured, using the radioactive microsphere technique before and 60 min after glucose administration.
Journal ArticleDOI
A Biosynthetic Control on Structures Serving as Ligands for Selectins: The Precursor Structures, 3-Sialyl/Sulfo Galβ1,3/4GlcNAcβ-0-R, Which Are High Affinity Substrates for α1,3/4-L-Fucosyltransferases, Exhibit the Phenomenon of Substrate Inhibition
TL;DR: The phenomenon of substrate inhibition, serving as acceptors at lower concentrations and as inhibitors at higher concentrations, was exhibited by the anionic acceptors; the Hill plots gave the Ki values 342.7 μM, 13.03 mM and 13.36 mM respectively for fetuin triantennary sialo glycopeptide, 3′-SulfoLacNAc and 3-sulfoGalβ1,3GlcNAcβ-O-Allyl.
Journal ArticleDOI
Kinetics of interleukin-2 induced changes in rigidity of human natural killer cells.
Robert J. Melder,Rakesh K. Jain +1 more
TL;DR: The findings suggest that the initial activation of human NK cells by IL-2 will produce a relatively rapid increase in rigidity that may cause entrapment of these cells in small capillaries in vivo and that removal of IL-1 will produce an additional increase in Rigidity, which is associated with decreased functional activity.
Journal ArticleDOI
Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy.
TL;DR: The ability of these agents to reprogram the immunosuppressive tumor microenvironment into an immunostimulatory milieu has rekindled interest, and has led to the FDA-approval of 7 different combinations of VEGF/VEGFR pathway inhibitors with immune checkpoint blockers for many solid tumors in the past 3 years.